Common Side Effects Patients Experience with Verzenio
Verzenio (abemaciclib), used with endocrine therapy for HR-positive, HER2-negative breast cancer, causes side effects in most patients. Diarrhea affects over 80% of users, often starting in the first weeks and managed with anti-diarrheal meds like loperamide.[1][2] Fatigue hits about 65%, nausea around 45%, and low appetite in 35-40%. These typically improve over time but lead to dose adjustments in 40-50% of cases.[1]
Serious Side Effects and Warnings
Severe issues include low white blood cell counts (neutropenia in 37-46%), raising infection risk, and low red blood cells (anemia in 25-29%). Liver enzyme elevations occur in 10-15%, sometimes needing monitoring or discontinuation. Venous thromboembolism affects 5%, and interstitial lung disease is rare but fatal in some cases—patients report cough or shortness of breath.[1][2] The label warns against use with strong CYP3A inhibitors, which worsen toxicity.[1]
Side Effects by Treatment Duration and Combinations
In the MONARCH trials, side effects peak early with fulvestrant or aromatase inhibitors. Diarrhea grade 3+ drops from 20% in cycle 1 to under 5% later. Combining with letrozole or anastrozole increases nausea but not as much as with palbociclib combos.[1][3] Long-term use (over 2 years) sees persistent low-grade fatigue and diarrhea in 20-30%.[3]
How Side Effects Compare to Ibrance and Kisqali
Verzenio's diarrhea rate (90%) exceeds Ibrance (palbociclib, 25-30%) and Kisqali (ribociclib, 20-35%), but neutropenia is similar across CDK4/6 inhibitors (40-60%). Verzenio allows continuous dosing without breaks, contributing to higher GI issues but steady efficacy.[2][3]
Patient Tips for Managing Verzenio Side Effects
Start loperamide at first loose stool, up to 16 mg/day initially. Eat small, bland meals for nausea; hydration prevents dehydration from diarrhea. Blood tests every 2 weeks early on catch blood count drops. About 9% discontinue due to side effects, mostly GI-related.[1][2]
[1]: Verzenio Prescribing Information (FDA)
[2]: Verzenio Safety Profile (Eli Lilly)
[3]: MONARCH Trial Data (NEJM)